-Wall Street Journal Report
HC Wainwright & Co. Maintains Buy on Cocrystal Pharma, Lowers Price Target to $35
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cocrystal Pharma (NASDAQ:COCP) with a Buy and lowers the price target from $42 to $35.